105 related articles for article (PubMed ID: 28267080)
21. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
Takatori R; Takahashi KA; Tokunaga D; Hojo T; Fujioka M; Asano T; Hirata T; Kawahito Y; Satomi Y; Nishino H; Tanaka T; Hirota Y; Kubo T
Clin Exp Rheumatol; 2006; 24(5):546-54. PubMed ID: 17181924
[TBL] [Abstract][Full Text] [Related]
22. 5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis.
Pastore S; Stocco G; Moressa V; Zandonà L; Favretto D; Malusà N; Decorti G; Lepore L; Ventura A
Rheumatol Int; 2015 Apr; 35(4):619-27. PubMed ID: 25240429
[TBL] [Abstract][Full Text] [Related]
23. Associations of common polymorphisms in the thymidylate synthase, reduced folate carrier and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase genes with folate and homocysteine levels and venous thrombosis risk.
Gellekink H; Blom HJ; den Heijer M
Clin Chem Lab Med; 2007; 45(4):471-6. PubMed ID: 17439323
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.
Warren RB; Smith RL; Campalani E; Eyre S; Smith CH; Barker JN; Worthington J; Griffiths CE
Br J Dermatol; 2009 Feb; 160(2):438-41. PubMed ID: 19016697
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.
Malik F; Ranganathan P
Pharmacogenomics; 2013 Feb; 14(3):305-14. PubMed ID: 23394392
[TBL] [Abstract][Full Text] [Related]
26. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis.
Chandran V; Siannis F; Rahman P; Pellett FJ; Farewell VT; Gladman DD
J Rheumatol; 2010 Jul; 37(7):1508-12. PubMed ID: 20472929
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.
Qiu Q; Huang J; Lin Y; Shu X; Fan H; Tu Z; Zhou Y; Xiao C
Medicine (Baltimore); 2017 Mar; 96(11):e6337. PubMed ID: 28296761
[TBL] [Abstract][Full Text] [Related]
28. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
[TBL] [Abstract][Full Text] [Related]
29. Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients.
Woo HI; Kim JA; Jung HA; Kim KK; Lee JY; Sun JM; Ahn JS; Park K; Lee SY; Ahn MJ
Pharmacogenomics; 2015; 16(4):383-91. PubMed ID: 25823786
[TBL] [Abstract][Full Text] [Related]
30. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
[TBL] [Abstract][Full Text] [Related]
31. Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.
Galbiatti AL; Castro R; Caldas HC; Padovani JA; Pavarino EC; Goloni-Bertollo EM
Tumour Biol; 2013 Dec; 34(6):3765-71. PubMed ID: 23838799
[TBL] [Abstract][Full Text] [Related]
32. Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling.
Li M; Jin C; Xu M; Zhou L; Li D; Yin Y
Cell Commun Signal; 2017 Dec; 15(1):52. PubMed ID: 29246230
[TBL] [Abstract][Full Text] [Related]
33. Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis.
Huang J; Fan H; Qiu Q; Liu K; Lv S; Li J; Yang H; Shu X; Xu Y; Lu X; Lu C; Zhang Y; Xiao C
Ther Adv Chronic Dis; 2020; 11():2040622320916026. PubMed ID: 32426102
[TBL] [Abstract][Full Text] [Related]
34. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.
Lambrecht L; Sleurs C; Labarque V; Dhooge C; Laenen A; Sinnaeve F; Renard M; Uyttebroeck A
Pharmacogenomics; 2017 Jun; 18(8):787-795. PubMed ID: 28592186
[TBL] [Abstract][Full Text] [Related]
35. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis.
Schmeling H; Biber D; Heins S; Horneff G
J Rheumatol; 2005 Sep; 32(9):1832-6. PubMed ID: 16142884
[TBL] [Abstract][Full Text] [Related]
36. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
[TBL] [Abstract][Full Text] [Related]
37. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS
Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680
[TBL] [Abstract][Full Text] [Related]
38. Genetic Polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR Are Related to the Outcome of Methotrexate Therapy for Rheumatoid Arthritis in a Chinese Population.
Lv S; Fan H; Li J; Yang H; Huang J; Shu X; Zhang L; Xu Y; Li X; Zuo J; Xiao C
Front Pharmacol; 2018; 9():1390. PubMed ID: 30546311
[No Abstract] [Full Text] [Related]
39. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
